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enzymes encoded by cancer-associated
IDH1 and IDH2 gene mutations produce
an oncometabolite, (R)-2HG. Fu et al.
discover a growth-suppressive function
of (R)-2-HG mediated by its binding and
inhibition of ATP synthase. The resulting
OXPHOS perturbation imparts extra
vulnerability to glucose limitation in IDH
mutant glioblastoma cells.
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We discovered recently that the central metab-
olite a-ketoglutarate (a-KG) extends the lifespan of
C. elegans through inhibition of ATP synthase and
TOR signaling. Here we find, unexpectedly, that
(R)-2-hydroxyglutarate ((R)-2HG), an oncometabolite
that interferes with various a-KG-mediated pro-
cesses, similarly extends worm lifespan. (R)-2HG
accumulates in human cancers carrying neomorphic
mutations in the isocitrate dehydrogenase (IDH) 1
and 2 genes. We show that, like a-KG, both (R)-2HG
and (S)-2HG bind and inhibit ATP synthase and inhibit
mTOR signaling. These effects are mirrored in IDH1
mutant cells, suggesting a growth-suppressive func-
tion of (R)-2HG. Consistently, inhibition of ATP syn-
thase by 2-HG or a-KG in glioblastoma cells is suffi-
cient for growth arrest and tumor cell killing under
conditions of glucose limitation, e.g., when ketone
bodies (instead of glucose) are supplied for energy.
These findings inform therapeutic strategies and
open avenues for investigating the roles of 2-HG and
metabolites in biology and disease.
INTRODUCTION
Aberrant metabolism, long symbolic of inherited metabolic dis-
eases, is now recognized as a hallmark of many other patho-508 Cell Metabolism 22, 508–515, September 1, 2015 ª2015 Elseviegenic conditions, including cancer (Warburg, 1956; Vander Hei-
den et al., 2009). Recently, we discovered that the common
metabolite a-ketoglutarate (a-KG) increases the lifespan of
adult C. elegans by inhibiting the highly conserved ATP syn-
thase and the TOR pathway, mimicking dietary restriction in
longevity (Chin et al., 2014). Furthermore, the observation that
a-KG inhibits mTOR function in normal human cells implies a
role for a-KG as an endogenous tumor suppressor metabolite
(Chin et al., 2014). Known for its role in central carbon meta-
bolism as a tricarboxylic acid (TCA) cycle intermediate, a-KG
is universal to all cellular life. a-KG also serves as a co-sub-
strate for a large family of dioxygenases with functions in
cellular processes such as hypoxic response and epigenetic
regulation. The identification of a-KG as a regulator of ATP syn-
thase reveals a new mechanism for longevity regulation through
metabolite signaling and suggests that there likely exist other
metabolites that play signaling roles in aging. Particularly, me-
tabolites that are similar in structure to a-KG may also modify
lifespan through interactions with ATP synthase, and the life-
span effects of metabolites may correlate with their involve-
ment in human disease.
In the TCA cycle, a-KG is produced from isocitrate by isoci-
trate dehydrogenase (IDH). Catalytic arginine mutations in
the IDH1 and IDH2 genes found in gliomas and acute
myeloid leukemia (AML) result in neomorphic enzymes that,
instead, convert a-KG to the structurally similar (R)-2-hydroxy-
glutarate ((R)-2HG), which accumulates to exceedingly high
levels in these patients (Dang et al., 2009; Gross et al., 2010;
Ward et al., 2010; Xu et al., 2011). (R)-2HG is now considered
an oncometabolite, impairing epigenetic and hypoxic regula-
tion through its binding to a-KG-dependent dioxygenases (Lur Inc.
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Figure 1. 2-HG Extends the Lifespan of
Adult C. elegans
(A) Chemical structures of 2-hydroxyglutaric acid
and a-ketoglutaric acid.
(B) (R)-2HG-supplemented worms. The mean life-
span (days of adulthood) with vehicle treatment
(mveh) = 14.0 (n = 112 animals tested).ma-KG = 20.7
(n = 114), p < 0.0001 (log-rank test);m(R)-2HG = 20.0
(n = 110), p < 0.0001 (log-rank test); mMet = 14.7
(n = 116), p = 0.4305 (log-rank test); mLeu = 13.2
(n = 110), p = 0.3307 (log-rank test).
(C) (S)-2HG-supplementedworms.mveh = 15.7 (n =
85); ma-KG = 21.5 (n = 99), p < 0.0001 (log-rank
test); m(S)-2HG = 20.7 (n = 87), p < 0.0001 (log-rank
test).
All metabolites were given at a concentration of
8 mM. Two independent experiments were per-
formed.et al., 2012; Koivunen et al., 2012). The development of inhib-
itors of mutant IDH that normalize (R)-2HG levels is an attrac-
tive cancer therapeutic strategy (Wang et al., 2013; Rohle
et al., 2013). Paradoxically, however, brain cancer patients
with IDH mutations have a longer median overall survival
than patients without mutations (Parsons et al., 2008; Yan
et al., 2009; van den Bent et al., 2010), hinting at additional
complexity in the biology of these cancers. (R)-2HG and (S)-
2-hydroxyglutarate ((S)-2HG) have also been found to accumu-
late in tissues of individuals with germline mutations in genes
encoding the corresponding 2-HG dehydrogenases (Kranen-
dijk et al., 2012; Steenweg et al., 2010). The resulting 2-HG
aciduria is associated with neurological manifestations whose
molecular mechanisms are unknown (Kranendijk et al., 2010).
We set out to identify additional targets of 2-HG to elucidate
the mechanisms underlying the seemingly disparate 2-HG-
related phenotypes.RESULTS AND DISCUSSION
2-HG Extends the Lifespan of Adult C. elegans
We have demonstrated that a-KG promotes longevity through
inhibition of ATP synthase (Chin et al., 2014). Given the structural
similarity between a-KG and 2-HG (Figure 1A) and the asso-
ciation of 2-HG with cancer and neurological dysfunction, we
asked whether 2-HG influences longevity. Surprisingly, both
(R)-2HG and (S)-2HG increase the lifespan ofC. elegans (Figures
1B and 1C). Notably, (R)-2HG, (S)-2HG, and a-KG interact
distinctly with the a-KG-dependent dioxygenases (Koivunen
et al., 2012; Tarhonskaya et al., 2014). Therefore, the similar ef-
fect of a-KG and (R)- and (S)-2-HG on lifespan points to a com-
mon mechanism that is independent of dioxygenases or any
enantiomer-specific 2-HG effects (da Silva et al., 2002; Latini
et al., 2005; Wajne et al., 2002; Chan et al., 2015). Because we
identified the ATP synthase b subunit (ATP5B) as a target of
a-KG (Chin et al., 2014), we askedwhether 2-HG acts by a similar
mechanism.Cell MeATP Synthase Is a Molecular Target of 2-HG
To determine whether 2-HG targets ATP5B, we first performed a
drug affinity-responsive target stability (DARTS) analysis (Lome-
nick et al., 2009) using U87 human glioblastoma cells. We found
that both (R)-2HG and (S)-2HG bind to ATP5B (Figure 2A; data
not shown). Like a-KG, both 2-HG enantiomers inhibit ATP syn-
thase (complex V) (Figures 2B and 2C; Figures S1A–S1C). This
inhibition is specific because there is no inhibition by either
enantiomer on other electron transport chain (ETC) complexes
(Figures S1D–S1F) or ADP import into the mitochondria (Fig-
ure S1G). The inhibition of ATP synthase by 2-HG is also readily
detected in live cells. Treatment of U87 cells (wild-type IDH1/2)
with membrane-permeable octyl esters of 2-HG or a-KG results
in decreased cellular ATP content (Figure S2A) and a decreased
ATP/ADP ratio (Figure 2D; Figure S2B) under mitochondrially
oxidative phosphorylation (OXPHOS) conditions, as with the
ATP synthase inhibitor oligomycin (Figures S2A and S2B). As ex-
pected, both basal and ATP synthase-linked oxygen consump-
tion rates (OCRs) are decreased in 2-HG-treated cells (Figure 2E;
Figures S2C and S2D), and lifespan increase by 2-HG is depen-
dent on ATP synthase (Figure S2E).
IDH1(R132H)Mutant Cells HaveDecreased ATPContent
and Mitochondrial Respiration
At normal cellular concentrations of200 mM (Gross et al., 2010),
(R)-2HG is unlikely to cause significant inhibition of ATP syn-
thase. However, in glioma patients with IDH mutations where
(R)-2HG accumulates to 10–100 times of natural levels (Dang
et al., 2009; Gross et al., 2010), inhibition of ATP synthase would
be possible. To test this idea, we used U87 cells stably ex-
pressing IDH1(R132H), the most common IDH mutation in
glioma (Yan et al., 2009). Similar to octyl (R)-2HG-treated
cells, U87/IDH1(R132H) cells exhibit decreased ATP content
and ATP/ADP ratio (Figure 3A) and OCR (Figure 3B) compared
with isogenic IDH1(WT)-expressing U87 cells. Importantly, the
decrease in respiration in IDH1(R132H) cells is attributable
to ATP synthase (complex V) inhibition. Although there is a




Figure 2. 2-HG Binds and Inhibits ATP Synthase
(A) DARTS identifies ATP5B as a 2-HG binding protein. U87 cell extracts were used. Succinate served as a negative control.
(B) Inhibition of ATP synthase by 2-HG. 2-HG, released from octyl 2-HG (600 mM), decreases (p < 0.001) state 3, but not state 4o or 3u, respiration in mitochondria
isolated from mouse liver. Octanol was used as vehicle. Oligo, oligomycin; FCCP, carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone; AA, antimycin A.
(C) Inhibition of submitochondrial particle ATPase by 2-HG acid but not by succinic acid. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; NS, p > 0.05. Oligo,
oligomycin (32 mM).
(D) Decreased ATP/ADP ratio in U87 cells treated with octyl 2-HG but not octyl citrate, indicating specificity and excluding any effect involving octanol. *p < 0.05,
***p < 0.001; NS, p > 0.05.
(E) Decreased respiration as indicated by OCR (**p < 0.01) in octyl 2-HG-treated U87 cells in glucose medium. Octanol shows no effect on OCR compared
with DMSO.
For (A)–(E), results were replicated in at least two independent experiments. Unpaired t test, two-tailed, two-sample unequal variance was used for (B)–(E).
Mean ± SD is plotted.versus U87/IDH1(R132H) cells, oligomycin-insensitive respira-
tion, which is independent of complex V, is not significantly
different between IDH1(WT) and IDH1(R132H) cells (Figure 3C).
Furthermore, complex V knockdown using ATP5B RNAi nor-
malizes the respiration difference between IDH1(R132H) and
IDH1(WT) cells (Figure 3D). Consistently, the difference in ATP510 Cell Metabolism 22, 508–515, September 1, 2015 ª2015 Elseviecontent of U87/IDH1(WT) and U87/IDH1(R132H) cells is dimin-
ished upon treatment with octyl (R)-2HG (Figure 3E). Similar re-
sults were obtained in HCT 116 IDH1(R132H/+) cells (Figures
S3A and S3B). In addition, the mitochondrial membrane poten-
tial in IDH1mutant cells is higher than in IDH1wild-type cells (Fig-





Figure 3. Inhibition of ATP Synthase in IDH1(R132H) Cells
(A) Decreased ATP levels and ATP/ADP ratio in U87/IDH1(R132H) cells (****p < 0.0001).
(B) Decreased respiration in U87/IDH1(R132H) cells (**p = 0.0037).
(C and D) Decreased respiration in U87/IDH1(R132H) cells is complex V-dependent (**p < 0.01, ***p < 0.001; NS, p > 0.05).
(E) Decreased ATP content in U87/IDH1(R132H) cells is attributable to (R)-2HG (****p < 0.0001; NS, p > 0.05).
(F) Increased mitochondrial membrane potential in U87/IDH1(R132H) cells normalized to cell number (****p < 0.0001).
(G) 2-HG accumulation in U87/IDH1(R132H) cells (***p = 0.0003).
(H) Metabolic profile of octyl (R)-2HG-treated U87 cells (***p < 0.001, *p = 0.0435). It is possible that the flux rate changed without affecting the absolute
abundance of the intermediates.
(I) Model of metabolite signaling through ATP synthase inhibition.
Unpaired t test, two-tailed, two-sample unequal variance was used for (A)–(H). Mean ± SD is plotted. Results were replicated in at least two independent
experiments.
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(Johnson et al., 1981). In contrast, inhibition of ETC complex I, III,
or IV causes dissipation of the mitochondrial membrane poten-
tial (Johnson et al., 1981).
The intracellular (R)-2HG levels are 20- to 100-fold higher in
U87 and HCT 116 cells expressing IDH1(R132H) than in control
cells (Figure 3G; Figure S3D). The elevated (R)-2HG levels are
comparable with those found in cells treated with octyl (R)-
2HG (Figure 3H), and levels reported for IDH1mutant tumor sam-
ples (Dang et al., 2009; Gross et al., 2010; Reitman et al., 2011).
The detection of similar (R)-2HG levels in tumors as in octyl (R)-
2HG-treated cells suggests that the tumor cells likely experience
reduced ATP synthase andmitochondrial respiration, raising po-
tential prognostic or therapeutic implications (see below).
2-HG Accumulation Does Not Alter the Levels of
Common Metabolites
The metabolite 2-HG is linked to the TCA cycle and related
amino acid metabolic pathways (Figure 3I). To explore potential
metabolic changes upon octyl 2-HG treatment, we measured
metabolite levels in octyl 2-HG-treated cells cultured in 1,2-13C-
glucose-containing medium by liquid chromatography/mass
spectrometry (LC/MS). As expected, 2-HG accumulates 20- to
100-fold more after octyl 2-HG treatment (Figure 3H; Figure S3E).
There is no dramatic change (<2-fold) in TCA cycle metabolites or
related amino acids (Figure 3H; Figure S3E). As expected, the bulk
of the increased 2-HG came from the hydrolysis of exogenously
provided octyl 2-HG, as indicated by the unlabeled M+0 iso-
topomer (Figure S3F; data not shown for octyl (S)-2HG treatment).
There is also nomajor change (<2-fold) in labeled TCA cycle inter-
mediates and related amino acids (Figure S3G). Similarly, treat-
ment with octyl a-KG causes an increase in a-KG levels without
other substantial changes in the metabolic profile (Figure S3H).
The steady-state metabolic profiles observed in 2-HG-treated
(or a-KG-treated) cells support the notion that the bioenergetic
shift results from the direct inhibition of ATP synthase by 2-HG
(or a-KG) rather than secondary effects (Figure 3I).
IDH1(R132H) Mutant Cells Exhibit Intrinsic Vulnerability
to Glucose Limitation
As the end component of the mitochondrial ETC, ATP synthase is
a major source of cellular energy and the sole site for OXPHOS
(Walker, 2013). When glycolysis is inhibited, for example, under
conditions of glucose insufficiency, cells are forced to rely
on mitochondrial respiration as a source of ATP. The inherent
inhibition of ATP synthase andmitochondrial respiration inmutant
IDH1 cancer cells therefore suggests a potential Achilles heel for
these cancers. Supporting this idea, when cultured in glucose-
free, galactose-containing medium to ensure that respiration is
the primary source of energy, IDH1(R132H) cells exhibit drasti-
cally decreased cell viability (Figure 4A; Figure S4A). These
results indicate a particular sensitivity of IDH1(R132H) mutant
cells to the deprivation of glucose. The mutant cell line is not
sensitive to fetal bovine serum (FBS) deprivation (data not shown),
indicating that its increased vulnerability to glucose starvation is
specific. This vulnerability to glucose starvation is also evident
in U87 cells treated with octyl a-KG or octyl 2-HG (Figures 4B–
4D; Figure S4B) and in ATP5B knockdown cells (Figure 4E).
These findings raise the possibility that cancer cells with the
IDH1(R132H) mutation (and the concomitant ATP synthase/mito-512 Cell Metabolism 22, 508–515, September 1, 2015 ª2015 Elseviechondrial respiration defect) may also be particularly sensitive to
nutrient conditions analogous to glucose limitation.
In complex organisms, glucose limitation canoccur as a conse-
quence of ketosis, wherein cells use ketone bodies (instead of
glucose) for energy. Ketosis is naturally induced upon prolonged
starvation (or fasting), during which cells derive energy from fat
reservoirs while sparing protein in muscle and other tissues from
catabolism. Ketosis can also be induced by feeding a low-carbo-
hydrate, high-fat ‘‘ketogenic diet,’’ which has shown benefits
against cancer (Stafford et al., 2010). One reason for this may be
that tumor cells largely dependonglucose for growthand survival.
Because the metabolism of ketone bodies depends entirely on
OXPHOS, one prediction is that inhibiting ATP synthase (or other
ETC components) in cancer cells would confer a survival disad-
vantage if ketone bodieswere the only source of energy. Because
U87 cells are unable to utilize ketone bodies for energy, we deter-
mined the effect of ketogenic conditions using HCT 116 cells ex-
pressing mutant IDH1. When cultured in glucose-free medium
containing the ketone body (R)-3-hydroxybutyrate, IDH1 mutant
HCT 116 cells showed a profound decrease in viability compared
with the parental cells (Figure 4F), confirming the suspectedmeta-
bolic weakness of IDHmutant cells. These results further support
our discovery that (R)-2HG accumulation in mutant IDH cancer
cells results in ATP synthase inhibition and also suggest novel
metabolic therapeutic strategies in cancer treatment.
Decreased mTOR Signaling and Cell Growth by 2-HG
Inhibition of ATP synthase leads to decreased TOR signaling in
mammalian cells, worms, and flies (Chin et al., 2014; Sun et al.,
2014). We found that ATP5B knockdown (Figure 4G), treatment
with octyl esters of 2-HG (Figure 4H), and IDH1(R132H) mutation
(Figure 4I) all decrease the phosphorylation of mTOR complex 1
substrates. This effect occurs initially (4 h) in an AMPK-indepen-
dent manner, with 2-HG decreasing mTOR signaling without
significantly altering AMPK activity. However, prolonged expo-
sure to 2-HG (24 h) also activates AMPK (Figure S4C), consistent
with the idea that mTOR itself may directly sense ATP (Dennis
et al., 2001) in addition to responding to AMP levels through
crosstalk with AMPK (Shaw, 2009; Inoki et al., 2012).
TOR is a major regulator of cell growth (Blagosklonny and
Hall, 2009). Consistent with the decreased TOR signaling, we
observed growth inhibition in ATP5B knockdown cells (Fig-
ure S4D), in cells treated with octyl a-KG or octyl 2-HG (Figures
S4E–S4G), and in IDH1(R132H)-expressing cells (Figures S4H
and S4I). ATP5B RNAi normalizes the growth difference be-
tween IDH1(R132H) and IDH1(WT) cells (Figure S4J). Growth
inhibition by 2-HG (and by a-KG) is also observed in WI-38
normal human diploid fibroblasts, in immortalized non-malig-
nant HEK293 cells, and in other cancer cell lines tested (Figures
S4K–S4N). These results suggest that, when present in excess,
2-HG acts as a growth-inhibitory metabolite across cell types.
Further work is warranted to test whether the growth-inhibitory
effect of (R)-2HG underlies the longer median overall survival of
glioma patients with IDH mutations.
SUMMARY
We demonstrate that, similar to a-KG, both enantiomers of




Figure 4. Inherent Vulnerability, or the Loss of Cell Viability, Characteristic of Cells with ATP5B Knockdown, 2-HG Accumulation, or IDH
Mutations
(A) U87/IDH1(R132H) cells have increased vulnerability to glucose starvation (***p < 0.001).
(B–D) Octyl a-KG- or octyl 2-HG-treated U87 cells exhibit decreased viability upon glucose starvation (****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05).
(E) ATP5B knockdown inhibits U87 cell growth (***p = 0.0004).
(F) HCT 116 IDH1(R132H/+) cells exhibit increased vulnerability to glucose-free medium supplemented with (R)-3-hydroxybutyrate (***p < 0.001).
(G–I) U87 cells with ATP5B knockdown or octyl esters of a-KG or 2-HG treatment and HCT 116 IDH1(R132H/+) cells exhibit decreased mTOR complex 1 activity
in glucose-free, galactose-containing medium.
For (A)–(E), cells were cultured in galactose medium. All lanes in (I) are on the same blot. Spaces indicate the positions of unnecessary lanes that were removed
digitally. Octanol has no effect on mTOR activity. Unpaired t test, two-tailed, two-sample unequal variance was used for (A)–(F). Mean ± SD is plotted. Results in
(A)–(I) were replicated in at least two independent experiments.C. elegans. Inhibition of ATP synthase by these related metabo-
lites decreases mitochondrial respiration and mTOR signaling.
Both 2-HG and a-KG exhibit broad growth-inhibitory effects
and reduce cancer cell viability under glucose-restricted condi-
tions. It is now recognized that (R)-2HG, which accumulates in
IDH mutant cancers, facilitates oncogenic transformation. Little
is known, however, about how (R)-2HG modifies the phenotype
of IDHmutant gliomas when the tumors are formed. Our findings
suggest that, in addition to interfering with various a-KG binding
factors with importance in cancer, (R)-2HG also acts, through
inhibition of ATP synthase and mTOR signaling downstream, toCell Medecrease tumor cell growth and viability. The latter property
may contribute to the improved prognosis of IDH mutant glioma
patients. This idea is consistent with emerging findings that the
inhibition of ETC complex I in cancer could be an effective ther-
apeutic strategy (Wheaton et al., 2014; Birsoy et al., 2014).
Together, these findings highlight a hopeful approach to cancer
prevention and treatment by targeting certain aging pathways
through metabolic modulation.
The effects of excess 2-HG are likely to be context-depen-
dent. Although its growth-inhibitory effects may be beneficial in
cancer, in 2-HG aciduria, the inhibition of ATP synthase andtabolism 22, 508–515, September 1, 2015 ª2015 Elsevier Inc. 513
the resulting impaired mitochondrial function could contribute to
neurological dysfunction (da Silva et al., 2002;Wajne et al., 2002;
Ko¨lker et al., 2002; Latini et al., 2005). Therefore, the identifica-
tion of ATP synthase as a target of both 2-HG enantiomers
provides a congruent molecular basis for 2-HG-associated
cancer and neurological disorders. We postulate that altered
mitochondrial energy metabolism may contribute to the inverse
susceptibility to cancer and neurodegenerative diseases (e.g.,
Parkinson’s disease). Finally, our findings raise the possibility
that nutrient and/or metabolic intervention per se, such as diets
that lower the reliance on glucose, and/or approaches that
perturb cellular energy metabolism (e.g., by targeting OXPHOS),
may benefit glioma patients. Such approaches may be particu-
larly valuable for improving the survival of glioma patients without
IDH mutations, who otherwise have no means to inherently curb




Lifespan experiments were performed as described previously (Chin et al.,
2014). Lifespan assays were conducted at 20C on solid nematode growth
medium (NGM). L4 or young adult animals were placed onto NGM assay
plates containing D-2-HG (Sigma, catalog no. H8378), L-2-HG (Sigma,
catalog no. 90790), a-KG (Sigma, catalog no. K1128), or vehicle control
(H2O). Assay plates were seeded with OP50. For RNAi experiments, NGM
assay plates also contained 1 mM isopropyl-b-D-thiogalactoside (IPTG) and
50 mg/ml ampicillin and were seeded with the appropriate RNAi feeding clone
(Thermo Scientific/OpenBiosystems). The C. elegans TOR (let-363) RNAi
clone was obtained from Joseph Avruch (Massachusetts General Hospital/
Harvard). To assess the survival of the worms, the animals were prodded
with a platinum wire every 2–3 days, and those that failed to respond were
scored as dead. Worms that ruptured, bagged, or crawled off the plates
were censored. Lifespan data were analyzed using GraphPad Prism. p Values
were calculated using the log-rank (Mantel-Cox) test unless stated otherwise.
Target Identification Using DARTS
DARTS was performed as described previously (Lomenick et al., 2009).
Measurement of Mitochondrial Respiration
Mitochondrial respiration was analyzed using isolated mitochondria (Brand
andNicholls, 2011). Animal studies were performed under approvedUniversity
of California Los Angeles (UCLA) animal research protocols.
Cell Growth and Viability Assays
Cells were seeded in 12-well plates and, after overnight incubation, treated
with the indicated concentrations of each compound. After harvesting, cells
were stained with acridine orange (AO) and 40,6-diamidino-2-phenylindole
(DAPI). Cell number and viability were measured based on AO and DAPI fluo-
rescence as measured by NC3000 (ChemoMetec) following the manufac-
turer’s instructions.
Metabolic Profile Analysis
Cells were cultured for 24 hr and rinsed with PBS, and medium containing
1,2-13C-glucose (1 g/l) was added. After 24-hr culture, cells were rinsed with
ice-cold 150 mM NH4AcO (pH 7.3), followed by addition of 400 ml cold meth-
anol and 400 ml cold water. Cells were scraped off and transferred to an
Eppendorf tube, and 10 nmol norvaline as well as 400 ml chloroform were
added to each sample. For the metabolite extraction, samples were vortexed
for 5 min on ice and spun down, and the aqueous layer was transferred into
a glass vial and dried. Metabolites were resuspended in 70% ACN, and a
5-ml sample was loaded onto a Phenomenex Luna 3u NH2 100A (150 3
2.0 mm) column. The chromatographic separation was performed on an
UltiMate 3000RSLC (Thermo Scientific) with mobile phases A (5 mM NH4AcO514 Cell Metabolism 22, 508–515, September 1, 2015 ª2015 Elsevie[pH 9.9]) and B (ACN) and a flow rate of 300 ml/ min. The gradient ran from 15%
A to 95%Aover 18min, 9min isocratic at 95%A, and re-equilibration for 7min.
Metabolite detection was achieved with a Thermo Scientific Q Exactive mass
spectrometer run in polarity switching mode (+3.0 kV /2.25 kV). TraceFinder
3.1 (Thermo Scientific) was used to quantify metabolites as the area under the
curve using retention time and accurate mass measurements (%3 ppm). Rela-
tive amounts of metabolites were calculated by summing up all isotopomers of
a given metabolite and normalized to the internal standard and cell number.
Natural occurring 13C was accounted for as described by Yuan et al. (2008).
Statistical Analyses
All experiments were repeated at least two times with identical or similar re-
sults. Data represent biological replicates. Appropriate statistical tests were
used for every figure. Mean ± SD is plotted in all figures. See the Supplemental
Experimental Procedures for details.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.cmet.2015.06.009.
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